Sunshine Biopharma Inc.: Form 10-Q for the period ended Jun 30, 2012
Filed with the SEC on Aug 8, 2012 and accepted by EDGAR at Aug 8, 2012, 08:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-04-01 to 2012-06-30 | $0 | us-gaap:SalesRevenueGoodsNet |
| Revenue | 6 months2012-01-01 to 2012-06-30 | $0 | us-gaap:SalesRevenueGoodsNet |
| Research and development | 3 months2012-04-01 to 2012-06-30 | $1.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2012-01-01 to 2012-06-30 | $1.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2012-04-01 to 2012-06-30 | −$102.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-01-01 to 2012-06-30 | −$142.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-04-01 to 2012-06-30 | $375 | us-gaap:InterestExpense |
| Interest expense | 6 months2012-01-01 to 2012-06-30 | $391 | us-gaap:InterestExpense |
| Net income | 3 months2012-04-01 to 2012-06-30 | −$103.1k | us-gaap:NetIncomeLoss |
| Net income | 6 months2012-01-01 to 2012-06-30 | −$142.4k | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2012-04-01 to 2012-06-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2012-01-01 to 2012-06-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2012-01-01 to 2012-06-30 | −$59.9k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2012-06-30 | $63.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-06-30 | $109.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2012-06-30 | $109.0k | us-gaap:Assets |
| Total liabilities | At period end2012-06-30 | $29.4k | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-06-30 | $79.6k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-12-003912. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.